Lung Cancer Screening in Real World Has High False-Positive Rate
By Kelly YoungEdited by: David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD A pair of studies in JAMA Internal Medicine illustrate the difficulties of implementing lung cancer screening. In the first, eight Veterans Health Administration medical centers identified and screened patients using low-dose computed tomography (LDCT). Over 2100 patients who were eligible for screening based […]
Opportunities and challenges for lung cancer screening in China
Chuanli Ren, Chongxu Han Abstract China accounts for nearly half of the incidence and mortality of lung cancer in the world. Furthermore, trends in lung cancer in China are increasing younger in age and the situation is deteriorating. As a whole although screening for early lung cancer may cause a small fraction of overdiagnosis and anxiety of […]
BioMark Contributes Additional Scientific Publication
Vancouver, British Columbia – (March 14th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “Use of amantadine as substrate for SSAT-1 activity as a reliable clinical diagnostic assay for breast and lung cancer” has been published in the peer-reviewed journal Future Science OA. […]
BioMark Announces New Patent Granted in China
Vancouver, British Columbia – (March 12, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX); (FSE: 20B); (OTCMKTS: BMKDF) is pleased to announce that its patent titled “DETECTION AND QUANTIFICATION OF ACETYLAMANTADINE IN URINE SAMPLES” has been granted in China on February 15, 2019. Rashid Ahmed, President and CEO, says, “Granting of this patent expands […]
Dr. Myron Weisfedlt Joins BioMark’s Scientific Advisory Team
Vancouver, British Columbia – (November 5th, 2018) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCQB: BMKDF) is pleased to announce that Dr. Myron Weisfeldt will be joining BioMark’s Scientific Advisory Team. Mr. Rashid Ahmed, CEO and President of BioMark Diagnostics says: “We are extremely proud and honored to have Dr. Myron Weisfeldt […]
BioMark Closes Final Tranche of Private Placement Offering
October 4th, 2018 – Vancouver, British Columbia – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that further to its press release of September 20, 2017, it has closed the final tranche of a non-brokered private placement for gross proceeds of $222,100.00 wherein BioMark issued 2,221,000 […]
Dr. Sandeep Singhal Joins BioMaark Scientific Advisory Team
Vancouver, British Columbia – (October 2nd, 2018) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that it has appointed Dr. Sandeep Singhal to its scientific advisory team. Rashid Ahmed, President and CEO, says, “We are delighted to welcome Dr. Singhal into our scientific advisory team. He provides expertise […]
BioMark Contributes in Scientific Publication
Vancouver, British Columbia – (September 26, 2018) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article spermidine/spermine N1-acetyltransferase-1 as a diagnostic biomarker in human cancer has been published in the peer-reviewed journal Future Science OA. Rashid Ahmed, President and CEO, says, “We are extremely excited […]
Dr. Paramjit Tappia Joins BioMark Scientific Advisory Team
Vancouver, British Columbia – (September 19th, 2018) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that it has appointed Dr. Paramjit Tappia to its scientific advisory team. Rashid Ahmed, President and CEO, says, “We are extremely excited to welcome Dr. Tappia into our scientific advisory team. His […]
BioMark Partners with Alberta Machine Intelligence Institute to Amplify Clinical Diagnostic Decision Making
Vancouver, British Columbia – (April 25, 2018) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCMKTS: BMKDF) is pleased to announce that it has penned a deal with the Alberta Machine Intelligence Institute (Amii) led by Dr. Osmar Zaïane of the University of Alberta’s Department of Computing Science and his team to assess and […]